Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer

被引:35
作者
Astsaturov, Igor
Cohen, Roger B.
Harari, Paul
机构
[1] Univ Wisconsin, Dept Human Oncol, Sch Med & Publ Hlth, Madison, WI 53792 USA
[2] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
关键词
cetuximab; epidermal growth factor receptor; head and neck cancer; radiation; tyrosine kinase inhibitor;
D O I
10.1586/14737140.6.9.1179
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this review, key aspects of epidermal growth factor receptor (EGFR) biology and the fruitful translation of these fundamental findings into recent treatment advances in head and neck squamous cell cancer (HNSCC) are highlighted. In contrast to a number of contemporary reviews of the EGFR, many of which focus on colorectal and nonsmall cell lung cancer, this review discusses the EGFR as a validated therapeutic target in HNSCC. Recent data confirm a survival advantage for the addition of the anti-EGFR monoclonal antibody cetuximab to definitive radiation therapy in locoregionally advanced HNSCC patients, as well as palliative benefits for patients with incurable recurrent and metastatic HNSCC. Small-molecule EGFR tyrosine kinase inhibitors also show considerable promise in this disease, both alone and in combination with radiation and chemotherapy. Both classes of anti-EGFR agent are generally well tolerated, with side effects (notably skin rash) that are distinct from the toxicities of conventional chemotherapy. Ongoing clinical trials will more clearly define the role for EGFR inhibitors in all treatment phases of HNSCC.
引用
收藏
页码:1179 / 1193
页数:15
相关论文
共 139 条
[1]  
ABIDOYE OO, 2006, J CLIN ONCOL S, V24, P5568
[2]   Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer [J].
Adelstein, DJ ;
Li, Y ;
Adams, GL ;
Wagner, H ;
Kish, JA ;
Ensley, JF ;
Schuller, DE ;
Forastiere, AA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :92-98
[3]  
AGULNIK M, 2006, J CLIN ONCOL, V24, P5566
[4]  
Akimoto T, 1999, CLIN CANCER RES, V5, P2884
[5]   An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors [J].
Amador, ML ;
Oppenheimer, D ;
Perea, S ;
Maitra, A ;
Cusati, G ;
Iacobuzio-Donahue, C ;
Baker, SD ;
Ashfaq, R ;
Takimoto, C ;
Forastiere, A ;
Hidalgo, M .
CANCER RESEARCH, 2004, 64 (24) :9139-9143
[6]  
Ang KK, 2002, CANCER RES, V62, P7350
[7]   Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues:: Variation in staining intensity due to choice of fixative and storage time of tissue sections [J].
Atkins, D ;
Reiffen, KA ;
Tegtmeier, CL ;
Winther, H ;
Bonato, MS ;
Störkel, S .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2004, 52 (07) :893-901
[8]   The effect of ionizing radiation on signal transduction: Antibodies to EGF receptor sensitize A431 cells to radiation [J].
Balaban, N ;
Moni, J ;
Shannon, M ;
Dang, LO ;
Murphy, E ;
Goldkorn, T .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1996, 1314 (1-2) :147-156
[9]   Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin [J].
Baselga, J ;
Pfister, D ;
Cooper, MR ;
Cohen, R ;
Burtness, B ;
Bos, M ;
D'Andrea, G ;
Seidman, A ;
Norton, L ;
Gunnett, K ;
Falcey, J ;
Anderson, V ;
Waksal, H ;
Mendelsohn, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :904-914
[10]   Critical update and emerging trends in epidermal growth factor receptor targeting in cancer [J].
Baselga, J ;
Arteaga, CL .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2445-2459